Marshall Wace, LLP Immuneering Corp Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.28 - $2.75 $491,616 - $1.06 Million
384,075 New
384,075 $491,000
Q3 2022

Nov 14, 2022
BUY
$5.0 - $14.32 $335,800 - $961,731
67,160 New
67,160 $962,000
Q4 2021

Feb 14, 2022
SELL
$16.12 - $31.02 $211,961 - $407,881
-13,149 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$17.0 - $32.84 $223,533 - $431,813
13,149 New
13,149 $349,000

Others Institutions Holding IMRX

# of Institutions
41
Shares Held
4.64M
Call Options Held
0
Put Options Held
0
View Full List

About Immuneering Corp

IMRX Quotes by TradingView
  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $57.8M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email